Biosimilars – Market Events And Forecast – Forecast Methodology And General Market Assumptions

In 2019 sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these same therapy areas and regions totaled approximately $3 billion. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and region.

Table of contents

  • Biosimilars - Market Events And Forecast - Forecast Methodology And General Market Assumptions
    • Brands Included in Market Forecast
    • General Market Assumptions
      • Clinical Trials
        • Approval Times and Market Launch Delays
          • Key Regulatory Review and Launch Delay Assumptions
          • United States
          • EU5
          • Japan
        • Indication Extrapolation
          • Pharmacy-Level Substitution
            • Biosimilar Pricing
              • Reference-Brand Pricing
                • Biosimilar Adoption Rates
                  • Key Assumptions
                  • Biosimilar Adoption Rates
                  • United States
                  • EU5
                  • Japan